{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:54:26Z","timestamp":1789350866516,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102398","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:00:55Z","timestamp":1751976055000},"page":"102398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Efficacy of Lutetium-177 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7608-7837","authenticated-orcid":false,"given":"Zineddine","family":"Belabaci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed","family":"Sleiay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Abdelshafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zina","family":"Otmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsayed S.","family":"Moubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faten","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2025.102398_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clinicians"},{"key":"10.1016\/j.clgc.2025.102398_bib0002","series-title":"Molecular & Diagnostic Imaging in Prostate Cancer","first-page":"117","article-title":"Castration-resistant prostate cancer: mechanisms, targets and treatment","author":"Mansinho","year":"2018"},{"issue":"2","key":"10.1016\/j.clgc.2025.102398_bib0003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/cancers17020205","article-title":"An updated systematic review and network meta-analysis of first-line triplet vs. Doublet therapies for metastatic hormone-sensitive prostate cancer","volume":"17","author":"Matsukawa","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.clgc.2025.102398_bib0004","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","article-title":"The androgen axis in recurrent prostate cancer","volume":"10","author":"Mohler","year":"2004","journal-title":"Clin Ca Res"},{"issue":"13","key":"10.1016\/j.clgc.2025.102398_bib0005","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","article-title":"Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer","volume":"11","author":"Titus","year":"2005","journal-title":"Clin Ca Res"},{"issue":"1","key":"10.1016\/j.clgc.2025.102398_bib0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13014-018-1037-7","article-title":"Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches","volume":"13","author":"Awang","year":"2018","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102398_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with177 Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102398_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","author":"Ahmadzadehfar","year":"2015","journal-title":"EJNMMI Res"},{"issue":"7","key":"10.1016\/j.clgc.2025.102398_bib0009","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177 Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.clgc.2025.102398_bib0010","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with177 Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.clgc.2025.102398_bib0011","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as A novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102398_bib0012","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.clgc.2025.102398_bib0013","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102398_bib0014","doi-asserted-by":"crossref","unstructured":"Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. doi:10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.clgc.2025.102398_bib0015","doi-asserted-by":"crossref","unstructured":"Sterne J.A.C., Savovi\u0107 J., Page M.J., et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. doi:10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"issue":"5","key":"10.1016\/j.clgc.2025.102398_bib0016","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102398_bib0017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10459","key":"10.1016\/j.clgc.2025.102398_bib0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102398_bib0019","unstructured":"Sartor et al. Efficacy of 177Lu- PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). doi:https:\/\/doi.org\/10.1016\/annonc\/annonc1623"},{"issue":"5","key":"10.1016\/j.clgc.2025.102398_bib0020","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","article-title":"177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial","volume":"49","author":"Satapathy","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.clgc.2025.102398_bib0021","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.2967\/jnumed.123.266141","article-title":"[177 Lu]Lu-PSMA-617 versus Docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: final survival analysis of a phase 2 randomized, controlled trial","volume":"64","author":"Satapathy","year":"2023","journal-title":"J Nucl Med"},{"issue":"10276","key":"10.1016\/j.clgc.2025.102398_bib0022","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2025.102398_bib0023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102398_bib0024","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2025.102398_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.121","article-title":"Efficacy of177 Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis","volume":"43","author":"Yazdanpanah","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2025.102398_bib0026","doi-asserted-by":"crossref","first-page":"S964","DOI":"10.1016\/j.annonc.2024.08.1680","article-title":"1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: third interim analysis of PSMAfore","volume":"35","author":"Fizazi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102398_bib0027","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34","author":"Sartor","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102398_bib0028","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","article-title":"Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review","volume":"23","author":"Patell","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.clgc.2025.102398_bib0029","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A Systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177\u2013labeled prostate-specific membrane antigen\u2013targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102398_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11523-024-01117-1","article-title":"Defining the position of [177Lu]Lu-PSMA radioligand therapy in the treatment landscape of metastatic castration-resistant prostate cancer: a meta-analysis of clinical trials","volume":"20","author":"Ciccarese","year":"2025","journal-title":"Targ Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102398_bib0031","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"Von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.clgc.2025.102398_bib0032","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102398_bib0033","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [177 Lu]Lu-PSMA\u2013Targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis","volume":"65","author":"Ells","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:25:06Z","timestamp":1757517906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1558767325000989"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102398","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Lutetium-177 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102398"}}